Advertisement

Drugs

, Volume 58, Issue 1, pp 79–88 | Cite as

Rituximab

  • Susan V. OnrustEmail author
  • Harriet M. Lamb
  • Julia A. Barman Balfour
Adis New Drug Profile

Abstract

  • ▴ Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells.

  • ▴ Rituximab reduced peripheral B lymphocyte counts by ≈90% within 3 days in patients with relapsed indolent lymphoma. Counts remained depleted for 6 months and recovered by months 9 to 12 after 4 doses of rituximab 375 mg/m2 once weekly.

  • ▴ Clinical response rates were 46 and 48% in 2 non-comparative trials in patients with relapsed indolent lymphoma. The rate of response to rituximab appeared to be markedly higher in patients with follicular lymphoma than in those with small lym-phocytic disease (56 or 60% versus 13 or 15%).

  • ▴ 85 to 94% of patients reported adverse events during clinical trials of rituximab; 90% of events were mild or moderate. The most common adverse event, a transient set of flu-like symptoms during the first infusion in approximately 50 to 87% of patients, generally resolved completely in <3 hours. Diphenhydramine and/or paracetamol was administered to some patients.

  • ▴ In 10% of patients, the flu-like symptoms during the first infusion were accompanied by broncho-spasm and/or hypotension or severe cytokine release syndrome. Patients were generally able to complete treatment after these symptoms resolved.

Keywords

Adis International Limited Clinical Response Rate Indolent Lymphoma Hematologic Malignancy Patient Relapse Indolent Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nadler LM. The malignant lymphomas. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill Inc., 1991: 1599–612Google Scholar
  2. 2.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 Sep 1; 84(5): 1361–92PubMedGoogle Scholar
  3. 3.
    Rosenberg SA, Berard CW, Brown BW, et al. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–35CrossRefGoogle Scholar
  4. 4.
    Fisher RI, Oken MM. Clinical practice guidelines: non-Hodgkin’s lymphomas. Cleve Clin J Med 1995; 62 Suppl. 1: 6–42Google Scholar
  5. 5.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low grade non-Hodgkin’s lymphomas. N Engl J Med 1984 Dec 6; 311: 1471–5PubMedCrossRefGoogle Scholar
  6. 6.
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993 Oct; 20 Suppl. 5: 75–88PubMedGoogle Scholar
  7. 7.
    Urba WJ, Longo DL. Lymphocytic lymphomas: clinical course and management. In: Moossa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology. 2nd ed. v. 2. Baltimore: Williams and Wilkins, 1991: 1277–95Google Scholar
  8. 8.
    Longo DL. Immunotherapy for non-Hodgkin’s lymphoma. Curr Opin Oncol 1996; 8: 353–9PubMedCrossRefGoogle Scholar
  9. 9.
    Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 Jan 15; 83(2): 435–45PubMedGoogle Scholar
  10. 10.
    Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12(3): 177–86PubMedCrossRefGoogle Scholar
  11. 11.
    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 Oct 15; 84: 2457–66PubMedGoogle Scholar
  12. 12.
    Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424–33PubMedGoogle Scholar
  13. 13.
    Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981 Jan; 67: 134–40PubMedCrossRefGoogle Scholar
  14. 14.
    Mathas S, Kommert K, Dörken B, et al. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation [abstract]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 405aGoogle Scholar
  15. 15.
    McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16: 2825–33PubMedGoogle Scholar
  16. 16.
    Czuczman M, Grillo-López AJ, White CA, et al. Rituxan/ CHOP chemoimmunotherapy in patients with low-grade or follicular (LG/F) non-Hodgkin’s lymphoma (NHL) [abstract]. J Immunother 1997; 20: 401CrossRefGoogle Scholar
  17. 17.
    Gianni AM, Magni M, Di Nicola M, et al. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose chemotherapy [abstract no. 481]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 119aGoogle Scholar
  18. 18.
    Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997 Oct; 15: 3266–74PubMedGoogle Scholar
  19. 19.
    Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997 Sep 15; 90: 2188–95PubMedGoogle Scholar
  20. 20.
    Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive forrelapse than detection in bone marrow. Blood 1994 Jun 15; 83(12): 3800–7PubMedGoogle Scholar
  21. 21.
    Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 trans-location is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993 Jun 15; 81(12): 3449–57PubMedGoogle Scholar
  22. 22.
    Gupta RK, Summers KE, Lister TA. PCR analysis for the t(14;18) translocation in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8) [abstract no. 974]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 239aGoogle Scholar
  23. 23.
    Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998; 9: 995–1001PubMedCrossRefGoogle Scholar
  24. 24.
    Piro L, White CA, Grillo-Lopez AJ, et al. Rituxan™(rituximab, IDEC-C2B8): interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin’s lymphoma [abstract no. 2272]. Blood 1997 Nov 15; 90 Suppl. 1, Part 1: 510aGoogle Scholar
  25. 25.
    Davis T, Levy R, White CA, et al. Rituximab: phase II (PII.) retreatment (ReRx) study in patients (pts) with low-grade or follicular (LG/F) NHL [abstract no. 1710]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 414aGoogle Scholar
  26. 26.
    Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of recurrent follicular lymphoma (FL) with rituximab (IDEC-C2B8): preliminary results of an ongoing UK multi-centre trial [abstract no. P-0969]. Br J Haematol 1998 Jul; 102(1): 243Google Scholar
  27. 27.
    Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waidenstrom’s macroglobulinemia (WM), and small lymphocytic lymphoma (SLL) with rituximab (IDEC-C2B8): preliminary results of an ongoing international multicentre trial [abstract no. O-0586]. Br J Haematol 1998 Jul; 102(1): 149Google Scholar
  28. 28.
    Piro L, White CA, Grillo-López AJ, et al. Rituximab in patients (pts) with relapsed low-grade or follicular non-Hodgkin’s lymphoma (LG/F NHL): response rate and duration with a weekly times 8 dosing regimen [abstract no. 49]. Proc Am Soc Clin Oncol 1999; 18: 14aGoogle Scholar
  29. 29.
    Janakiraman N, McLaughlin P, White CA, et al. Rituximab: correlation between effector cells and clinical activity in NHL [abstract no. 1384]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 337aGoogle Scholar
  30. 30.
    McLaughlin P, Grillo-Lopez AJ, Maloney DG, et al. Efficacy controls and long term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LB/F) NHL [abstract no. 1712]. Blood 1998 Nov 15; 92 Suppl. l, Part 1: 414aGoogle Scholar
  31. 31.
    Maloney DG, Davis T, Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. Reply [letter]. J Clin Oncol 1998 Apr; 16: 1636–7Google Scholar
  32. 32.
    Kinoshita T, Nagai H, Murate T, et al. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter]. J Clin Oncol 1998 Dec; 16(12): 3916PubMedGoogle Scholar
  33. 33.
    Davis T, Levy R, White CA, et al. Retreatments with RITUXAN (rituximab, Idec-C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin’s lymphoma (NHL) [abstract no. 2269]. Blood 1997 Nov 15; 90 Suppl. 1, Part 1: 509Google Scholar
  34. 34.
    Hainsworth JD, Burris H, Scullin DC, et al. Rituximab induction and maintenance therapy in patients (pts) with previously untreated low-grade non-Hodgkin’s lymphoma (NHL): preliminary results of Minnie Pear Cancer Research Network phase II trial [abstract no. 105]. Proc Am Soc Clin Oncol 1999; 18: 29Google Scholar
  35. 35.
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999 Jan; 17(1): 268–76PubMedGoogle Scholar
  36. 36.
    Czuczman M, Grillo-Lopez AJ, White CA, et al. Rituximab/ CHOP chemoimmunotherapy in patients (pts) with low grade lymphoma (LG/F NHL): progression free survival (FPS) after three years (median) follow up. 1999, Roche Pharmaceuticals, data on fileGoogle Scholar
  37. 37.
    Davis T, Maloney D, White CA, et al. Combination immunotherapy of low grade or follicular non-Hodgkins lymphoma with rituximab and alpha interferon: interim analysis [abstract no. 39]. Proc Am Soc Clin Oncol 1998 May; 17: 11aGoogle Scholar
  38. 38.
    Coiffier B. Rituximab in diffuse large B cell and mantle cell lymphomas [abstract no. 020]. Ann Oncol 1998; 9 Suppl. 3: 27Google Scholar
  39. 39.
    Tsai DE, Moore HCF, Porter DL, et al. Progressive intermediate grade non-Hodgkin’s lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab [abstract no. 1713]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 415aGoogle Scholar
  40. 40.
    Fisher RI. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996; 7 Suppl. 6: S35–9PubMedCrossRefGoogle Scholar
  41. 41.
    Byrd JC, White CA, Link B, et al. Rituximab therapy in previously treated Waldenstrom’s macroglobulinemia: preliminary evidence of activity [abstract no. 433]. Blood 1998 Nov 15; 92 Suppl. 1, Pt 1: 106aGoogle Scholar
  42. 42.
    Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL [abstract no. 7]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 3aGoogle Scholar
  43. 43.
    NewsEdge Corporation. Roche’s rituximab European warnings strengthened following eight cases of severe cytokine release syndrome; Idec/Genentech discussing Rituxan labeling revisions with FDA. Health News Daily [online], 1 Dec 1998, Media release, downloaded 3 Dec 1998Google Scholar
  44. 44.
    Janeway CA, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd, 1994Google Scholar
  45. 45.
    IDEC Pharmaceuticals Corporation, Genentech Inc. Rituxan (rituximab) prescribing information. Revised 1998 SepGoogle Scholar
  46. 46.
    Anonymous. Fatal ADRs with Roche’s MabThera. Scrip 1998 Dec 4; 2393: 17Google Scholar
  47. 47.
    Hoffmann-La Roche AG. MABTHERA (Rituximab) prescribing information. Revised 27 Nov 1998Google Scholar
  48. 48.
    Byrd JC, Waselenko JK, Maneatis TA, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis [abstract no. 432]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 106aGoogle Scholar
  49. 49.
    Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999 Mar; 17(3): 791–5PubMedGoogle Scholar
  50. 50.
    Winkler U, Jensen M, Manzke O, et al. Severe side effects in patients with B-cell chromic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab [abstract no. 4228]. Blood 1998 Nov 15; 92 Suppl. 1, Part 2: 285bGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Susan V. Onrust
    • 1
    Email author
  • Harriet M. Lamb
    • 1
  • Julia A. Barman Balfour
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations